Emerging targets in cancer drug resistance

Abstract

Drug resistance is a complex phenomenon that frequently develops as a failure to chemotherapy during cancer treatment. Malignant cells increasingly generate resistance to various chemotherapeutic drugs through distinct mechanisms and pathways. Understanding the molecular mechanisms involved in drug resistance remains an important area of research for identification of precise targets and drug discovery to improve therapeutic outcomes. This review highlights the role of some recent emerging targets and pathways which play critical role in driving drug resistance.

Keywords

Drug resistance / transforming growth factor-β / Keap1-Nrf2 / PI3K-Akt / FOXO transcription factors / focal adhesion kinases / annexins / MIEN1 / gene splicing / sphingolipids / microRNA

References

[1] Goodman LS,Dameshek W,McLennan MT.Nitrogen mustard therapy: the use of methyl-bis(β-chloroethyl) amine hydrochloride and tris(\sb-chlorethyl) amine hydrochloride for Hodgkin’s disease, lymphosarcoma, leukemia, and certain allied and miscellaneous disorders..JAMA1946;132:126-32

[2] Holohan C,Longley DB.Cancer drug resistance: an evolving paradigm..Nat Rev Cancer2013;13:714-26

[3] Gottesman MM.Mechanisms of cancer drug resistance..Annu Rev Med2002;53:615-27

[4] Glavinas H,Cserepes J.The role of ABC transporters in drug resistance, metabolism and toxicity..Curr Drug Deliv2004;1:27-42

[5] McCubrey JA,Fitzgerald TL,Martelli AM.Roles of signaling pathways in drug resistance, cancer initiating cells and cancer progression and metastasis..Adv Biol Regul2015;57:75-101

[6] Cazenave LA,Myers CE.Robert FO.Glutathione S--transferase and drug resistance..Drug resistance in cancer therapy.1989;Boston, MASpringer171-87

[7] Zhang J,Ye ZW,Tew KD.Pleiotropic functions of glutathione S-transferase P..Adv Cancer Res2014;122:143-75 PMCID:PMC5079281

[8] Islam MT.Hallmarks of cancer drug resistance and overcoming ways: a paradigm..Int J Pharm Biol Arch2017;8:1-17

[9] Giancotti FG.Deregulation of cell signaling in cancer..FEBS lett2014;588:2558-70 PMCID:PMC4111980

[10] Choi CH.ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal..Cancer Cell Int2005;5:1-13 PMCID:PMC1277830

[11] Thomas H.Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein..Cancer Control2003;10:159-65

[12] Triller N,Kern I,Debeljak A.Multidrug resistance in small cell lung cancer: expression of P-glycoprotein, multidrug resistance protein 1 and lung resistance protein in chemo-naive patients and in relapsed disease..Lung Cancer2006;54:235-40

[13] Nooter K,Look MP,Henzen-Logmans SC.The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer..Br J Cancer1997;76:486-93 PMCID:PMC2227995

[14] Zalcberg J,Slater A,El-Osta S.MRP1 not MDR1 gene expression is the predominant mechanism of acquired multidrug resistance in two prostate carcinoma cell lines..Prostate Cancer Prostatic Dis2000;3:66-75

[15] Doyle LA,Abruzzo LV,Gao Y.A multidrug resistance transporter from human MCF-7 breast cancer cells..Proc Natl Acad Sci U S A1998;95:15665-70 PMCID:PMC28101

[16] Robey RW,Steadman K,Finley EM.Inhibition of ABCG2-mediated transport by protein kinase inhibitors with a bisindolylmaleimide or indolocarbazole structure..Mol Cancer Ther2007;6:1877-85

[17] Shukla S,Ambudkar SV.Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance..Drug Resist Updat2012;15:70-80 PMCID:PMC3348341

[18] Pusztai L,Ibrahim N,Theriault R.Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma..Cancer2005;104:682-91

[19] Ruff P,Jordaan JP,Moodley SD.A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen..Cancer Chemother Pharmacol2009;64:763-8

[20] Meijer C,Timmer-Bosscha H,Meersma GJ.Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds..Cancer Res1992;52:6885-9

[21] Schwartz PM,Hyde CM,Handschumacher RE.Role of uridine phosphorylase in the anabolism of 5-fluorouracil..Biochem Pharmacol1985;34:3585-9

[22] Houghton JA.Elucidation of pathways of 5-fluorouracil metabolism in xenografts of human colorectal adenocarcinoma..Eur J Cancer Clin Oncol1983;19:807-15

[23] Malet-Martino M.Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review..Oncologist2002;7:288-323

[24] Kosuri KV,Wang L,Otterson GA.An epigenetic mechanism for capecitabine resistance in mesothelioma..Biochem Biophys Res Commun2010;391:1465-70 PMCID:PMC2860267

[25] Belanger AS,Harvey M.Regulation of UGT1A1 and HNF1 transcription factor gene expression by DNA methylation in colon cancer cells..BMC Mol Biol2010;11:1-11 PMCID:PMC2835698

[26] Toffoli G,Gasparini G,Azzarello G.Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer..J Clin Oncol2010;28:866-71 PMCID:PMC4872310

[27] Pasche B.Role of transforming growth factor beta in cancer..J Cell Physiol2001;186:153-68

[28] Oshimori N,Fuchs E.TGF-β promotes heterogeneity and drug resistance in squamous cell carcinoma..Cell2015;160:963-76 PMCID:PMC4509607

[29] Chan K,Chang JC.NRF2, a member of the NFE2 family of transcription factors, is not essential for murine erythropoiesis, growth, and development..Proc Natl Acad Sci U S A1996;93:13943-8 PMCID:PMC19474

[30] Jung BJ,Shin S,Jeon SM.Dysregulation of NRF2 in cancer: from molecular mechanisms to therapeutic opportunities..Biomol Ther2018;26:57-68 PMCID:PMC5746038

[31] Ishida S,Thiele DJ.Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals..Proc Natl Acad Sci U S A2002;99:14298-302 PMCID:PMC137878

[32] Yee SW,Badagnani I,Klein TE.SLC19A1 pharmacogenomics summary..Pharmacogenet Genomics2010;20:708-15 PMCID:PMC2956130

[33] Hagner N.Cancer chemotherapy: targeting folic acid synthesis..Cancer Manag Res2010;2:293-301 PMCID:PMC3033035

[34] Morales C,Ribas M,Muñoz M.Dihydrofolate reductase amplification and sensitization to methotrexate of methotrexate-resistant colon cancer cells..Mol Cancer Ther2009;8:424-32

[35] Barabas K,Lurie D.Cisplatin: a review of toxicities and therapeutic applications..Vet Comp Oncol2008;6:1-8

[36] Surowiak P,Kaplenko I,Dolinska-Krajewska B.ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome..Clin Cancer Res2006;12:7149-58

[37] Davis NM,Stadelman K,Libra M.Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention..Oncotarget.2014;5:4603-50 PMCID:PMC4148087

[38] Barouch-Bentov R.Mechanisms of drug resistance in kinases..Expert Opin Investig Drugs2011;20:153-208 PMCID:PMC3095104

[39] Bonavia R,Narita Y,Vandenberg S.Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma..Genes Dev2010;24:1731-45 PMCID:PMC2922502

[40] Sun Y,Higano C,Porter P.Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B..Nat Med2012;18:1359-68 PMCID:PMC3677971

[41] Kang J,Kwon T,Kim JS.Plasminogen activator inhibitor-1 enhances radioresistance and aggressiveness of non-small cell lung cancer cells..Oncotarget.2016;7:23961-74 PMCID:PMC5029677

[42] Peters GJ.Fluoropyrimidines as antifolate drugs. In Antifolate Drugs in Cancer Therapy.1999;Totowa, NJHumana Press101-45

[43] Longley DB,Johnston PG.5-fluorouracil: mechanisms of action and clinical strategies..Nat Rev Cancer2003;3:330-8

[44] Marsh S.Thymidylate synthase pharmacogenetics in colorectal cancer..Clin Colorectal Cancer2001;1:175-8

[45] Longley DB,Boyer J,Lynch M.Characterization of a thymidylate synthase (TS)-inducible cell line: a model system for studying sensitivity to TS-and non-TS-targeted chemotherapies..Clin Cancer Res2001;7:3533-9

[46] Longley DB,Allen WL,Ferguson PR.The role of thymidylate synthase induction in modulating p53-regulated gene expression in response to 5-fluorouracil and antifolates..Cancer Res2002;62:2644-9

[47] Xu Y.Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity..Ann Oncol2002;13:1841-51

[48] Boyer J,Aroori S,McCulla A.Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan..Clin Cancer Res2004;10:2158-67

[49] Deffie AM,Gupta RS,Goldenberg GJ.Multifactorial resistance to antineoplastic agents in drug-resistant P388 murine leukemia, Chinese hamster ovary, and human HeLa cells, with emphasis on the role of DNA topoisomerase II..Biochem Cell Biol1992;70:354-64

[50] Friche E,Schmidt CA.Decreased DNA topoisomerase II in daunorubicin-resistant Ehrlich ascites tumor cells..Cancer Res1991;51:4213-8

[51] Jordan MA.Microtubules as a target for anticancer drugs..Nat Rev Cancer2004;4:253-65

[52] Jordan MA,Gardiner S,Copp H.Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death..Cancer Res1996;56:816-25

[53] Jordan MA,Thrower D.Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations..Proc Natl Acad Sci U S A1993;90:9552-6 PMCID:PMC47607

[54] Burkhart CA,Horwitz SB.The role of β-tubulin isotypes in resistance to antimitotic drugs..BBA-Rev Cancer2001;2:O1-9

[55] Giannakakou P,Kang YK,Buters JT.Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization..J Biol Chem1997;272:17118-25

[56] Stover EH,Matulonis UA.Biomarkers of response and resistance to DNA repair targeted therapies..Clin Cancer Res2016;22:5651-60

[57] Tanaka M,Suzuki H,Li D.Association of multi-drug resistance gene polymorphisms with pancreatic cancer outcome..Cancer2011;117:744-51 PMCID:PMC3017663

[58] Rodrigues AS, Gomes BC, Martins C, Gromicho M, Oliveira NG, et al. DNA repair and resistance to cancer therapy. In: Chen C, editor. New research directions in DNA repair. IntechOpen 2013. Available from: https://www.intechopen.com/books/new-research-directions-in-dna-repair/dna-repair-and-resistance-to-cancer-therapy. [Last accessed on 7 Jan 2019]

[59] Faragher AJ.Nek2A kinase stimulates centrosome disjunction and is required for formation of bipolar mitotic spindles..Mol Biol Cell2003;14:2876-89 PMCID:PMC165683

[60] Zhou W,Xia J,Salama ME.NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers..Cancer Cell2013;23:48-62 PMCID:PMC3954609

[61] Lord RV,Gandara D,Camps C.Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer..Clin Cancer Res2002;8:2286-91

[62] Kwon HC,Oh SY,Kim MC.Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer..Ann Oncol2007;18:504-9

[63] Usanova S,Sied U,Schneider A.Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression..Mol Cancer2010;9:1-11 PMCID:PMC3098011

[64] Tazi J,Stamm S.Alternative splicing and disease..BBA-Mol Basis Dis2009;1792:14-26 PMCID:PMC5632948

[65] Marani M,Hancock D,Lemoine NR.Identification of novel isoforms of the BH3 domain protein Bim which directly activate Bax to trigger apoptosis..Mol Cell Biol2002;22:3577-89 PMCID:PMC133811

[66] de Necochea-Campion R,Zhou Q,Chen CS.Aberrant splicing and drug resistance in AML..J Hematol Oncol2016;9:1-9 PMCID:PMC5018179

[67] Passiglia F,Castiglia M,Rizzo S.EGFR inhibition in NSCLC: New findings . . . . and opened questions?.Crit Rev Oncol Hematol2017;112:126-35

[68] Stark M,Avivi I.Aberrant splicing of folylpolyglutamate synthetase as a novel mechanism of antifolate resistance in leukemia..Blood2009;113:4362-9

[69] Wang Z,Liu Y.New development in CAR-T cell therapy..J Hematol Oncol2017;10:1-11 PMCID:PMC5320663

[70] Wang Y,Cruz C,Nacson J.The BRCA1-D11q alternative splice isoform bypasses germline mutations and promotes therapeutic resistance to PARP inhibition and cisplatin..Cancer Res2016;76:2778-90 PMCID:PMC4874568

[71] García-Becerra R,Díaz L.Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance..Int J Mol Sci2012;14:108-45 PMCID:PMC3565254

[72] Ma G,Wang K.SRC-3 has a role in cancer other than as a nuclear receptor coactivator..Int J Biol Sci2011;7:664-72 PMCID:PMC3107475

[73] Yan J,Tsai MJ.SRC-3/AIB1: transcriptional coactivator in oncogenesis..Acta Pharmacol Sin2006;27:387-94

[74] Catalanotto C,Zardo G.MicroRNA in control of gene expression: an overview of nuclear functions..Int J Mol Sci2016;17:1-17 PMCID:PMC5085744

[75] Shivdasani RA.MicroRNAs: regulators of gene expression and cell differentiation..Blood2006;108:3646-53 PMCID:PMC1895474

[76] Jalkanen AL,Wilusz J.Determinants and implications of mRNA poly (A) tail size-does this protein make my tail look big?.Semin Cell Dev Biol2014;34:24-32 PMCID:PMC4163081

[77] Liu H,Huang J,Guo L.miR-7 modulates chemoresistance of small cell lung cancer by repressing MRP 1/ABCC 1..Int J Exp Pathol2015;96:240-7 PMCID:PMC4561560

[78] Munoz JL,Ramkissoon SH,Greco SJ.Temozolomide resistance in glioblastoma occurs by miRNA-9-targeted PTCH1, independent of sonic hedgehog level..Oncotarget2015;6:1190-201 PMCID:PMC4359226

[79] Fang Y,Fu Y.MicroRNA-17-5p induces drug resistance and invasion of ovarian carcinoma cells by targeting PTEN signaling..J Biol Res-Thessalon2015;22:1-10 PMCID:PMC4619013

[80] Zhu X,Xie C,Liu Y.miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6..Int J Cancer2014;135:1286-96

[81] Li H,Sun X,Shi C.MicroRNA-181a regulates epithelial-mesenchymal transition by targeting PTEN in drug-resistant lung adenocarcinoma cells..Int J Oncol2015;47:1379-92

[82] De Mattos-Arruda L,Nuciforo PG,Giovannetti E.MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients..Oncotarget2015;6:37269-80 PMCID:PMC4741929

[83] Wang Z,Liu P,Situ H.MicroRNA-25 regulates chemoresistance-associated autophagy in breast cancer cells, a process modulated by the natural autophagy inducer isoliquiritigenin..Oncotarget2014;5:7013-26 PMCID:PMC4196180

[84] Zhang Y,Li C,Che X.miR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1..Tumor Biol2015;36:2277-85

[85] Lu L,Zhao H.MicroRNA-134 modulates resistance to doxorubicin in human breast cancer cells by downregulating ABCC1..Biotechnol Lett2015;37:2387-94

[86] Feng R.Knockdown of microRNA-127 reverses adriamycin resistance via cell cycle arrest and apoptosis sensitization in adriamycin-resistant human glioma cells..Int J Clin Exp Pathol2015;8:6107-16 PMCID:PMC4525822

[87] Wu Q,Xia L,Wu K.Methylation of miR-129-5p CpG island modulates multi-drug resistance in gastric cancer by targeting ABC transporters..Oncotarget2014;5:11552-63 PMCID:PMC4294356

[88] Shang Y,Liu Z,Ren G.miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1..Oncogene2014;33:3267-76

[89] To KK,Ng SS.Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer..Exp Cell Res2015;338:222-31

[90] Li JH,Zhong MZ,Wang JX.Inhibition of MicroRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line..Tumor Biol2016;37:2387-94

[91] van Jaarsveld MT,Boersma AW,van IWF.miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway..Mol Cancer2015;14:196 PMCID:PMC4650519

[92] Sui H,Pan SF,Wang YW.miR200c attenuates P-gp-mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer..Mol Cancer Ther2014;13:3137-51

[93] Shen X,Qi J,Wu X.Study on the association between miRNA-202 expression and drug sensitivity in multiple myeloma cells..Pathol Oncol Res2016;22:531-9

[94] Zhang AX,Yang YP,Li ZF.MicroRNA-217 overexpression induces drug resistance and invasion of breast cancer cells by targeting PTEN signaling..Cell Biol Int2015;42:1455

[95] Gullà A,Gallo Cantafio ME,Amodio N.A 13 mer LNA-i-miR-221 inhibitor restores drug sensitivity in melphalan-refractory multiple myeloma cells..Clin Cancer Res2016;22:1222-33 PMCID:PMC4775414

[96] Hiraki M,Takahashi H,Takahashi Y.Concurrent targeting of KRAS and AKT by MiR-4689 is a novel treatment against mutant KRAS colorectal cancer..Mol Ther Nucleic Acids2015;4:e231 PMCID:PMC4354340

[97] Zheng HC.The molecular mechanisms of chemoresistance in cancers..Oncotarget2017;8:59950-64 PMCID:PMC5601792

[98] Ho KK,Lam EW.Many forks in the path: cycling with FOXO..Oncogene2008;27:2300-11

[99] Myatt SS.The emerging roles of forkhead box (Fox) proteins in cancer..Nat Rev Cancer2007;7:847-59

[100] Lam EW,Petkovic M.FOXO transcription factors: key regulators of cell fate..Biochem Soc Trans2006;34:722-6

[101] Abounader R.Interactions between PTEN and receptor tyrosine kinase pathways and their implications for glioma therapy..Expert Rev Anticancer Ther2009;9:235-45 PMCID:PMC2678856

[102] Sunters A,Stahl M,Zoumpoulidou G.FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel treated breast cancer cell lines..J Biol Chem2003;278:49795-805

[103] Sunters A,Pomeranz KM,Brosens JJ.Paclitaxel-induced nuclear translocation of FOXO3a in breast cancer cells is mediated by c-Jun NH2-terminal kinase and Akt..Cancer Res2006;66:212-20

[104] Hui RC,Guest SK,Gomes AR.Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells..Mol Cancer Ther2008;7:670-8

[105] Hui RC,Constantinidou D,Karadedou CT.The forkhead transcription factor FOXO3a increases phosphoinositide-3 kinase/ Akt activity in drug-resistant leukemic cells through induction of PIK3CA expression..Mol Cell Biol2008;28:5886-98 PMCID:PMC2547013

[106] Saba R,Zacny JP.The role of forkhead box protein m1 in breast cancer progression and resistance to therapy..Int J Breast Cancer2016;2016:1-8 PMCID:PMC4752991

[107] Tan Y,Costa RH.Chk2 mediates stabilization of the FoxM1 transcription factor to stimulate expression of DNA repair genes..Mol Cell Biol2007;27:1007-16 PMCID:PMC1800696

[108] Park YY,Jennings NB,Peng G.FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair..Carcinogenesis2012;33:1843-53 PMCID:PMC3529559

[109] Monteiro LJ,Kongsema M,Man C.The Forkhead Box M1 protein regulates BRIP1 expression and DNA damage repair in epirubicin treatment..Oncogene2013;32:4634-45 PMCID:PMC3874579

[110] M Golubovskaya V.Focal adhesion kinase as a cancer therapy target..Anticancer Agents Med Chem2010;10:735-41 PMCID:PMC3267551

[111] van Nimwegen MJ.Focal adhesion kinase: a potential target in cancer therapy..Biochem pharmacol2007;73:597-609

[112] Ren XD,Sieg DJ,Schlaepfer DD.Focal adhesion kinase suppresses Rho activity to promote focal adhesion turnover..J Cell Sci2000;113:3673-8

[113] Roy-Luzarraga M.Molecular pathways: Endothelial cell FAK-a target for cancer treatment..Clin Cancer Res2016;22:3718-24 PMCID:PMC5386133

[114] Gilbert LA.DNA damage-mediated induction of a chemoresistant niche..Cell2010;143:355-66 PMCID:PMC2972353

[115] Lokman NA,Oehler MK.The role of annexin A2 in tumorigenesis and cancer progression..Cancer Microenviron2011;4:199-208 PMCID:PMC3170418

[116] Grindheim AK,Vedeler A.Protein phosphorylation and its role in the regulation of Annexin A2 function..Biochim Biophys Acta Gen Subj2017;1861:2515-29

[117] Xu XH,Kang LH,Song YQ.Association of annexin A2 with cancer development..Oncol rep2015;33:2121-8

[118] Spijkers-Hagelstein JA,Schneider P,Stam RW.Src kinase-induced phosphorylation of annexin A2 mediates glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia..Leukemia2013;27:1063-71

[119] Chen CY,Chen CH.Annexin A2-mediated cancer progression and therapeutic resistance in nasopharyngeal carcinoma..J Biomed Sci2018;25:1-10 PMCID:PMC5877395

[120] Liu X,Zhao B,Dong C.Low expression of KCNN3 may affect drug resistance in ovarian cancer..Mol Med Rep2018;18:1377-86 PMCID:PMC6072180

[121] Ong HL,Liu X,Paria BC.Dynamic assembly of TRPC1-STIM1-Orai1 ternary complex is involved in store-operated calcium influx Evidence for similarities in store-operated and calcium release-activated calcium channel components..J Biol Chem2007;282:9105-16 PMCID:PMC3309402

[122] Dasgupta S,Rauniyar N,Borejdo J.Novel gene C17orf37 in 17q12 amplicon promotes migration and invasion of prostate cancer cells..Oncogene2009;28:2860-72 PMCID:PMC2726905

[123] Rajendiran S,Hare RJ,Roby RK.MicroRNA-940 suppresses prostate cancer migration and invasion by regulating MIEN1..Mol cancer2014;13:1-15 PMCID:PMC4246551

[124] Leung TH,Chan KK,Cheung AN.The interaction between C35 and ΔNp73 promotes chemo-resistance in ovarian cancer cells..Br J Cancer2013;109:965-75 PMCID:PMC3749569

[125] Wang Y,Cai Y,Yuan X.Annexin A2 could enhance multidrug resistance by regulating NF-κB signaling pathway in pediatric neuroblastoma..J Exp Clin Cancer Res2017;36:1-16 PMCID:PMC5559827

[126] Liu S,Zhao M,Ren J.The homing and inhibiting effects of hNSCs-BMP4 on human glioma stem cells..Oncotarget.2016;7:17920-31 PMCID:PMC4951260

[127] Maziveyi M.Cell matrix adhesions in cancer: the proteins that form the glue..Oncotarget.2017;8:48471-87 PMCID:PMC5564663

[128] Annunziata CM.Novel facts about FAK: new connections to drug resistance?.J Natl Cancer Inst2013;105:1430-1

[129] Barreiro-Alonso A,García-Díaz R,Yu L.Delineating the HMGB1 and HMGB2 interactome in prostate and ovary epithelial cells and its relationship with cancer..Oncotarget.2018;9:19050-64 PMCID:PMC5922377

[130] Syed N,Sahasrabuddhe NA,Sathe G.Silencing of high-mobility group box 2 (HMGB2) modulates cisplatin and 5-fluorouracil sensitivity in head and neck squamous cell carcinoma..Proteomics2015;15:383-93 PMCID:PMC4528963

[131] Ukmar G,Raddrizzani L,Di Bella S.PATRI, a Genomics Data Integration Tool for Biomarker Discovery..BioMed Res Int2018;2018:1-13 PMCID:PMC6051285

[132] Katz E,Sims AH,Li J.A gene on the HER2 amplicon, C35, is an oncogene in breast cancer whose actions are prevented by inhibition of Syk..Br J Cancer2010;103:401-10 PMCID:PMC2920017

[133] Futerman AH.The complex life of simple sphingolipids..EMBO Rep2004;5:777-82 PMCID:PMC1299119

[134] Saddoughi SA,Ogretmen B.Roles of bioactive sphingolipids in cancer biology and therapeutics. In Lipids in Health and Disease.2008;DordrechtSpringer413-40 PMCID:PMC2636716

[135] Hinrichs JW,Kok JW.Rafts as missing link between multidrug resistance and sphingolipid metabolism..J Membr Biol2005;203:57-64

[136] Gouaze-Andersson V.Glycosphingolipids and drug resistance..Biochim Biophys Acta2006;1758:2096-103

[137] Gouaze V,Prickett CS,Giuliano AE.Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs..Cancer Res2005;65:3861-7

[138] Gouaze-Andersson V,Kreitenberg AJ,Giuliano AE.Ceramide and glucosylceramide upregulate expression of the multidrug resistance gene MDR1 in cancer cells..Biochim Biophys Acta2007;1771:1407-17 PMCID:PMC3569095

[139] Akao Y,Nakagawa Y,Kim TJ.High expression of sphingosine kinase 1 and S1P receptors in chemotherapy-resistant prostate cancer PC3 cells and their camptothecin-induced up-regulation..Biochem Biophys Res Commun2006;342:1284-90

[140] Alexander S,Alexander H.Dictyostelium discoideum to human cells: pharmacogenetic studies demonstrate a role for sphingolipids in chemoresistance..Biochim Biophys Acta2006;1760:301-9

[141] Baran Y,Senkal CE,Bielawski J.Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells..J Biol Chem2007;282:10922-34

[142] Huang X,Jahangiri S,Tran E.miRNA-95 mediates radioresistance in tumors by targeting the sphingolipid phosphatase SGPP1..Cancer Res2013;73:6972-86